CodeBreaK200 is the first phase III randomized trial of a KRAS inhibitor, wherein sotorasib (n = 171) was compared against docetaxel (n = 174) in second-line treatment of metastatic NSCLC. This evidence concerns the gene KRAS and non-small cell lung carcinoma.